Navigation Links
Nanotechnology Revolution To Be Spearheaded By European Union

European Union is aimed at restoring eyesight to thousands of patients with impaired eyesight. The technology works by rearranging a eye protein which could restore to natural cornea offering a perfect eyesight. This technique is better than transplants as it does not involve tissue rejection. The project could help the 28,000 people each year in the EU that have cornea operations. The EU has already spent 2.56 million euros (3.17 million dollars) on the project out of a total budget of 4.37 million euros (5.41 million dollars). Knee Nanotechnology project aims at restoring knee injury which is offered in Edinburgh. Cancer Nanotechnology project under the supervision of Doctor Andreas Jordan, Head of Magforce Nanotechnology, Berlin is working on insertion of ‘Nano’ cells directly into the cancer cells, by which it is made to burst.
br>
'"/>




Page: 1 2

Related medicine news :

1. CoQ10 bioavailability increased by Nanotechnology
2. RNA Nanotechnology To Rescue Cancer Patients In Future
3. Scientists Consider About New Technology Called Nanotechnology
4. Potential Benefits Of New Nanotechnology
5. Nanotechnology Promises Huge Medical Benefits
6. Nanotechnology at its best: Nanomotors And Mechanical Nanoswitches
7. Nanotechnology Could Revolutionize Cardiac Treatment
8. Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight
9. Nanotechnology – to detect and treat ovarian cance
10. Nanotechnology Used For Detecting Viruses
11. India, China Trying to Fight Disease With Nanotechnology
Post Your Comments:
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 1PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 2PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 1Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 2Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 4Back to normal 3A Surgery improves outcomes for spine patients 47438 1Back to normal 3A Surgery improves outcomes for spine patients 47438 2